Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus

  title={Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus},
  author={Mitra Niafar and Leili Pourafkari and Kavus Shahsavarinia and Nushin Milanchian and Farhad Niafar and Nader D. Nader},
  journal={Journal of Cardiovascular and Thoracic Research},
  pages={8 - 12}
Introduction: Quick release bromocriptine (BROM-QR), currently approved for glycemic control, reduces the risk of cardiovascular events in adults with type-2 diabetes mellitus (T2DM). This study evaluates the effect of BROM-QR on homocysteine (HOMC) and high sensitive C-reactive protein (hs-CRP), the biochemical markers of coronary atherosclerosis/inflammation, in patients with uncontrolled T2DM. Methods: In this non-randomized, before-and-after clinical trial, patients with uncontrolled T2DM… 
2 Citations

Figures and Tables from this paper

Late phase completed clinical trials investigating bromocriptine mesylate quick release as treatment of type 2 diabetes mellitus
Recommendations include bromocriptine mesylate QR as part of dual or triple antihyperglycemic therapy especially in individuals with type 2 diabetes who are hesitant to add injectable treatment options and/or have cardiovascular disease.
Distinct Effects of Royal Jelly on Human Endothelial Cells Under High Glucose Condition
Royal jelly is able to attenuate the abnormal status of 30 mM glucose condition in endothelial cells by different mechanisms.


Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
The present investigation was undertaken to more critically evaluate the impact of bromocriptine-QR on cardiovascular outcomes in this study subject population by including CV death in the above-described original composite analysis and stratifying this new analysis on the basis of multiple demographic subgroups.
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
Bromocriptine-QR therapy slowed the progression of CVD and metabolic disease in T2DM subjects in good glycemic control.
It is shown that women with hyperprolactinemic amenorrhea is associated with increased level of CRP and therapy with bromocriptine significantly reduced CRP, suggesting a possible anti-inflammatory action of bromOCriptine in addition to prolactin.
Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.
Elevated plasma tHcy levels in type 2 diabetes is associated with a higher prevalence of macroangiopathy and nephropathy when assessed from creatinine clearance indexes and is not associated with different degrees of insulin resistance.
Cardiovascular and Renal Effects of Bromocriptine in Diabetic Patients with Stage 4 Chronic Kidney Disease
Both BEC and PBO groups decreased blood pressure—but the effect was more pronounced in the BEC group, and BEC prevented the progression of CKD while maintaining the creatinine clearance unchanged.
Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels
Cabergoline was superior to bromocriptine in affecting 2‐hr post‐challenge plasma glucose levels, HOMA‐IR, as well as circulating levels of IGF‐1, FFA, uric acid, hsCRP, homocysteine, fibrinogen and 25‐hydroxyvitamin D.
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of bromocriptine-QR, a D2 dopamine receptor agonist, as a treatment for type 2 diabetes.
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
For patients with type 2 diabetes in whom maximal sulfonylurea therapy failed, the addition of the insulin sensitizer troglitazone seemed to have greater benefits on several traditional and novel CVRF than metformin therapy.
Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Bromocriptine improves glycemic control and glucose tolerance in obese type 2 diabetic patients and is associated with enhanced maximally stimulated insulin-mediated glucose disposal.
Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
  • Y. Keche
  • Medicine, Biology
    Journal of pharmacy & bioallied sciences
  • 2010
Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2